Add a New Bears Reason

Company: Amgen (AMGN)
Current price:
Headline: (100 character max)
Analysis:
Cancel
57%
agree
7 votes

  Competition in the dialysis market is inevitable

Competition in the dialysis market is inevitable - even though Amgen won its current patent case against Roche, there are many other products on the horizon that could take significant market share and many operate well outside of Amgen's patents - such as hematide, made by Affymax.

On July 7th, FMS announced it was purchasing APP pharmaceuticals, a key manufacturer of generic injectable oncology drugs. Amgen sells FMS ~ $1 Billion / year in EPO - a key injectable drug whose patents will expire in the next few years. Once EPO goes generic, FMS will probably just make it internally and cut Amgen out.

(100 character max) Cancel
55%
agree
9 votes

  Amgen is extremely vulnerable to changes in reimbursement for its drugs

Amgen is extremely vulnerable to changes in reimbursement for its drugs. Nowhere is this more evident than the recent National Coverage Decision by the government in oncology, which has severely limited the use of Aranesp in cancer patients. As commercial payors and the federal government look around for cost saving, Amgen will continue to be a prime target.

(100 character max) Cancel
0%
agree
0 votes

  See Peter Welch (D) NH effort on re-capture of 500mm

AMGN as the recipient of 500 mm from Congress is outlined in interview with Bill Moyers:

http://billmoyers.com/segment/u-s-rep-peter-welch-on-amgen%E2%80%99s-sweet-senate-deal/

While the actions of AMGN and the lawmakers may simply go the way so many issues of involvement the perfidy therein is alarming.

(100 character max) Cancel
40%
agree
5 votes

  Safety concerns over Amgen's erythropoietic products

Safety concerns over Amgen's erythropoietic products - which make up half of revenue - will lead to reductions in dose and less frequent use.

(100 character max) Cancel
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki